Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
Hanahan
D
D
Department of Biochemistry and Biophysics, Hormone Research Institute, University of California San Francisco, San Francisco, California 94143-0534, USA. dh@biochem.ucsf.edu
Bergers
G
G
Bergsland
E
E
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy; D003510:Cyclohexanes; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020714:Maximum Tolerated Dose; D051379:Mice; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009447:Neuroblastoma / Q000098:blood supply / Q000188:drug therapy; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors / Q000276:immunology; D040262:Receptors, Vascular Endothelial Growth Factor; D012717:Sesquiterpenes / Q000009:adverse effects / Q000627:therapeutic use; D014407:Tumor Cells, Cultured; D014747:Vinblastine / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D003510:Cyclohexanes; D017978:Receptors, Growth Factor; D012717:Sesquiterpenes; D014747:Vinblastine; D003520:Cyclophosphamide; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000077609:O-(Chloroacetylcarbamoyl)fumagillol